


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:


1. (Currently Amended) A compound of formula I




wherein

R₁ is a residue of formula (a), (b) or (c)


(a)



(b)



(c)



R₂ is $-(CR_{22}R_{23})_{1-3}-$ or $-C(O)-$;

each of R₃ and R₈ independently is S; O; or NR₂₄;

each of R₄ and R₅ independently is optionally R₂₅-substituted C₃-C₁₂ cycloalkyl, C₁-C₁₂ alkyl or saturated C₈₋₁₂ polycyclic residue; or optionally R₂₆- and/or R₂₇-substituted aryl, arylC₁₋₄alkyl or heteroaryl; wherein up to 4 carbon atoms of R₄ and/or R₅ are optionally substituted by S, O or NR₂₄;

R₆ is H; C₁-C₆ alkyl; C₃-C₆ cycloalkyl; or optionally R₂₆- and/or R₂₇-substituted aryl, arylC₁₋₄alkyl or heteroaryl;

R₇ is CR₂₈ or N;

R₉ is a direct bond; $-(CR_{22}R_{23})_{1-2}-$; or NR₂₄;

each of R₁₀₋₂₃ and R₂₈ independently is H; F; Cl; Br; C₁-C₆ alkyl; C₂-C₆ alkoxyalkyl; C₁-C₆ halogenoalkyl; C₃-C₆ cycloalkyl; optionally R₂₆- and/or R₂₇-substituted aryl or heteroaryl;

CONR₂₉R₃₀; COOR₂₉; CN; NO₂; or OR₃₁; or

two of R₁₀₋₁₉ which are attached to the same carbon atom, together with the carbon atom to which they are attached, form a 3-7 membered nonaromatic ring optionally containing up to two heteroatoms selected independently from N, O and S; or

R₁₇ and R₁₈, together with the C atoms to which they are attached, form a 4-7 membered nonaromatic ring optionally containing up to two heteroatoms selected independently from N, O and S; or

R₂₀ and R₂₁, together with the carbon atoms to which they are attached, form an optionally R₂₆- and/or R₂₇-substituted aryl or heteroaryl;

each of R₂₄, R₂₉ and R₃₀ independently is H; C₁-C₆ alkyl; C₂-C₆ alkoxyalkyl; C₁-C₆ halogenoalkyl; C₃-C₇ cycloalkyl; or optionally R₂₆- and/or R₂₇-substituted aryl, arylC₁₋₄alkyl or heteroaryl;

R₂₅ represents 1 to 4 substituents each independently having one of the significances given for R₁₀₋₂₃ above;

R₂₆ represents 1 to 4 substituents each independently selected from C₁-C₆ alkyl; C₁-C₆ hydroxyalkyl; C₂-C₆ alkoxyalkyl; C₁-C₆ halogenoalkyl; C₃-C₆ cycloalkyl; C₂-C₆ alkenyl; C₃-C₆ cycloalkenyl; C₂-C₆ alkynyl; aryl; heteroaryl; heteroaryl N-oxide; F; Cl; Br; I; OH; OR₄; CONH₂; CONHR₄; CONR₄R₄; OC(O)R₄; OC(O)OR₄; OC(O)NHR₄; OC(O)NR₄R₄; OSO₂R₄; COOH; COOR₄; CF₃; CHF₂; CH₂F; CN; NO₂; NH₂; NHR₄; NR₄R₄; NHC(O)R₄; NR₄C(O)R₄; NHC(O)NHR₄; NHC(O)NH₂; NR₄C(O)NHR₄; NR₄C(O)NR₄R₄; NHC(O)OR₄; NR₄C(O)OR₄; NHSO₂R₄; N(SO₂R₄)₂; NR₄SO₂R₄; SR₄; S(O)R₄; SO₂R₄; Si(CH₃)₃ and B(OC(CH₃)₂)₂;

R₂₇ represents two adjacent substituents which form an annulated 4-7 membered nonaromatic ring optionally containing up to two heteroatoms selected independently from N, O and S;

R₃₁ is C₁-C₆ alkyl; C₃-C₇ cycloalkyl; optionally R₂₆- and/or R₂₇-substituted aryl, arylC₁₋₄alkyl or heteroaryl; or CF₃;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 which is selected from 1,3-Dicyclohexyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1-Cyclohexyl-3-cyclopentyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1-Cycloheptyl-3-cyclohexyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1,3-Dicycloheptyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1-Cyclohexyl-3-cyclooctyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1,3-Dicyclohexyl-2-(6,6-dimethyl-5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1,3-Dicyclooctyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea and 1,3-Dicycloheptyl-2-(6,6-dimethyl-5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea.


3. (Original) A pharmaceutical composition comprising a compound according to claim 1 in free form or in a pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carrier therefor.

4. (Previously Presented) A method for prevention or treatment of disorders or diseases mediated by interactions between chemokine receptors, acute or chronic transplant rejection, inflammatory diseases, autoimmune diseases or proliferative diseases comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1.


5. (Previously Presented) A method for prevention or treatment of tumor invasiveness, symptoms associated with tumor growth, metastatic spread of tumours, tumor-associated angiogenesis or growth of micrometastases comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1.

6. (Previously Presented) A method for prevention or treatment of an infectious disease comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1.

7. (Original) A process for preparing a compound of formula I comprising reacting a compound of formula II



with a compound of formula III



wherein R_1 to R_6 are as defined in claim 1 and R_{32} is a leaving group;
and optionally converting a resultant compound of formula I obtained in free form to a salt form or vice versa.

8. (Previously Presented) A pharmaceutical combination comprising a compound according to claim 1 in free form or in a pharmaceutically acceptable salt form and a further agent selected from immunosuppressive, immunomodulating, anti-inflammatory, antiproliferative, antineoplastic, chemotherapeutic, anti-infective, anti-viral, and antibiotic agents, and agents for the treatment of acute myeloid leukemia.

9. (Original) Combination according to claim 8 comprising an antiretroviral agent, in particular an anti-HIV agent.

10. (Original) Use of a combination according to claim 9 for the manufacture of a medicament for preventing or combating an infectious disease, in particular viral infection or progression of AIDS.
11. (Previously Presented) A method of treatment or prevention of any of the following conditions:
- i) disorders or diseases mediated by interactions between chemokine receptors,
 - ii) acute or chronic transplant rejections,
 - iii) inflammatory or autoimmune diseases,
 - iv) proliferative diseases,
 - v) symptoms associated with tumor invasiveness or tumor growth,
 - vi) metastatic spreads of tumours, tumor-associated angiogenesis and growths of micrometastases,
 - vii) infectious diseases, in particular viral infections,
- comprising administering to said subject a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound according to claim 1 in free form or in a pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carrier therefor.
12. (Previously Presented) The method of claim 6 wherein said infectious disease is a viral infection.
13. (Previously Presented) The method of claim 12 wherein said viral infection is AIDS.
14. (Previously Presented) The method of claim 11 wherein the condition is a viral infection.
15. (Previously Presented) The method of claim 14 wherein said viral infection is AIDS.